Aarti Industries posts 75% YoY revenue jump in Q2FY27, EBITDA up 41%

⚡ Key Financial Takeaways

  • Revenue rose to Rs36.7 bn in Q2FY27, a 75% YoY increase, while EBITDA climbed 41% to Rs4.1 bn.
  • Energy segment benefited from elevated crude oil prices and higher gasoline‑naphtha cracks; non‑energy volumes were buoyed by NCB, DCB and pharma demand.
  • Management expects momentum to continue, citing new Zone IV capacity and upcoming long‑term contracts, but flags raw‑material cost pressure and working‑capital needs as risks.
  • Prabhudas Lilladher retains an Accumulate rating with a target price of Rs476, valuing the stock at 21× Sep'28 EPS versus a current 17× FY29 EPS.
  • Potential inventory losses and competitive pressure on PDA from Chinese imports remain watch‑points.

💡 Why It Matters

The earnings jump underscores Aarti Industries' capacity to translate higher raw‑material costs into revenue growth, a rare feat in a cost‑sensitive sector. Strong performance across both Energy and non‑energy segments signals diversified demand, reducing reliance on any single market. The Accumulate rating and elevated target price reflect analyst confidence, while the highlighted risks remind investors that cost volatility and competitive pressures remain material considerations.

Strong top‑line and profit growth Aarti Industries announced a robust Q2FY27 performance, posting revenue of **Rs36.7 billion**, up **75% year‑on‑year**. EBITDA rose to **Rs4.1 billion**, a **41% increase** from the same quarter last year. The surge was anchored by two main drivers: a sharp rise in sales volumes and the company's ability to pass through higher raw‑material costs to customers.

Energy and non‑energy segments both in favour The **Energy segment** recorded solid growth, helped by a rise in crude oil prices and wider gasoline‑naphtha crack spreads. Meanwhile, **non‑energy value chains**—including **NCB (Naphtha Cracking), DCB (Distillate Cracking) and pharmaceutical** segments—saw healthy volume expansion. The **PDA (Petrochemical Derivatives) business**, however, continues to feel pressure from Chinese imports priced below domestic levels.

Management outlook and operational focus Company leadership expects the current momentum to persist. Key pillars of the outlook include: - **Ramp‑up of newly commissioned Zone IV facilities**, which should lift capacity utilisation. - **Execution of long‑term contracts** already signed, providing revenue visibility. - **Continued demand improvement** across core value chains.

The firm also highlighted several risk factors that will be monitored closely: **elevated raw‑material prices**, **higher working‑capital requirements**, and the possibility of **inventory write‑downs**.

Analyst rating and valuation Prabhudas Lilladher maintains an **Accumulate** rating on Aarti Industries, setting a **target price of Rs476**. The valuation implies a **21× multiple on the projected Sep'28 earnings per share**, compared with the stock’s current **17× FY29 EPS** multiple.

What investors should watch - **Utilisation rates at Zone IV** as the plant reaches full operational capacity. - **Raw‑material price trends**, especially for key petrochemical feedstocks. - **Competitive dynamics in the PDA segment**, particularly any further price actions from Chinese exporters. - **Progress on long‑term contract sign‑offs**, which could underpin future revenue streams.

Overall, Aarti Industries’ Q2FY27 results suggest a strong near‑term earnings trajectory, but the company’s ability to manage cost pressures and inventory risks will be critical for sustaining growth.

🏛️ Background & Context

Aarti Industries is a leading Indian specialty chemicals manufacturer with a product portfolio spanning petrochemicals, pharmaceuticals and performance chemicals. The company has been expanding its production footprint, most recently adding the Zone IV complex, to meet rising domestic and export demand. The Indian chemicals sector has been navigating a backdrop of global raw‑material price swings and heightened competition from low‑cost producers, particularly in China.

👁️ What To Watch Next

Key upcoming developments include the full commissioning of Zone IV, the signing of additional long‑term supply contracts, and any shifts in global crude oil and feedstock pricing that could affect margin dynamics. Investors should also monitor inventory levels for potential write‑downs and the competitive response in the PDA market.

More in Business